Literature DB >> 9500467

Human lung cancer antigens recognized by autologous antibodies: definition of a novel cDNA derived from the tumor suppressor gene locus on chromosome 3p21.3.

A O Güre1, N K Altorki, E Stockert, M J Scanlan, L J Old, Y T Chen.   

Abstract

Serological analysis of a recombinant lung cancer cDNA expression library with the autologous patient serum led to the isolation of 20 clones representing 12 different genes: 4 of these were known genes, and the other 8 were previously unknown genes. Of the four known genes, aldolase A (NY-LU-1), previously shown to be overexpressed in lung cancer, was most frequently isolated. The other three genes were annexin XI, human HIV Rev-interacting protein Rip-1, and the human homologue of the ATP-binding arsA component of the bacterial arsenite transporter, all of which are known to be widely expressed in human tissues. Among the eight unknown genes, of most interest was NY-LU-12. Cloning of full-length NY-LU-12 showed that this cDNA was derived from the same gene as g16, a partially sequenced gene that mapped to the lung cancer tumor suppressor gene locus on chromosome 3p21. The reported g16 sequence, however, was significantly shorter (2433 versus 3591 bp). As a result of alternate splicing and subsequent frameshift, the reported g16 protein is 603 amino acids shorter than the NY-LU-12 product (1123 residues) at its COOH terminus and would therefore lack the epitopes recognized by the autologous serum. Analysis of the putative NY-LU-12 protein sequence predicted that it is a nuclear zinc finger protein with two RNA-binding domains, and Southern analysis showed that this gene is partially deleted in the lung cancer line NCI-H740 but not in nine other lung cancer lines. Screening of normal and cancer patient sera showed anti-NY-LU-12 seroreactivity in 2 of 21 allogeneic lung cancer patients but not in 24 patients with other tumors or in 16 sera from healthy donors. Comparison of NY-LU-12 cDNA from Lu15 tumor and normal lung tissue by DNA sequencing and/or single-strand conformation polymorphism analysis showed no evidence of mutation. Considering the high frequency of 3p21 alterations in lung cancer and the fact that the tumor suppressor gene or genes in this locus have not been identified, additional studies on the NY-LU-12 gene and its product are warranted.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9500467

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  22 in total

1.  Autoantibody biomarkers identified by proteomics methods distinguish ovarian cancer from non-ovarian cancer with various CA-125 levels.

Authors:  Aykan A Karabudak; Julie Hafner; Vivekananda Shetty; Songming Chen; Angeles Alvarez Secord; Michael A Morse; Ramila Philip
Journal:  J Cancer Res Clin Oncol       Date:  2013-09-03       Impact factor: 4.553

2.  Protein microarray signature of autoantibody biomarkers for the early detection of breast cancer.

Authors:  Karen S Anderson; Sahar Sibani; Garrick Wallstrom; Ji Qiu; Eliseo A Mendoza; Jacob Raphael; Eugenie Hainsworth; Wagner R Montor; Jessica Wong; Jin G Park; Naa Lokko; Tanya Logvinenko; Niroshan Ramachandran; Andrew K Godwin; Jeffrey Marks; Paul Engstrom; Joshua Labaer
Journal:  J Proteome Res       Date:  2010-11-23       Impact factor: 4.466

3.  Immunoprofiling using NAPPA protein microarrays.

Authors:  Sahar Sibani; Joshua LaBaer
Journal:  Methods Mol Biol       Date:  2011

Review 4.  The sentinel within: exploiting the immune system for cancer biomarkers.

Authors:  Karen S Anderson; Joshua LaBaer
Journal:  J Proteome Res       Date:  2005 Jul-Aug       Impact factor: 4.466

5.  An immune response manifested by the common occurrence of annexins I and II autoantibodies and high circulating levels of IL-6 in lung cancer.

Authors:  F M Brichory; D E Misek; A M Yim; M C Krause; T J Giordano; D G Beer; S M Hanash
Journal:  Proc Natl Acad Sci U S A       Date:  2001-08-14       Impact factor: 11.205

6.  Using protein microarray as a diagnostic assay for non-small cell lung cancer.

Authors:  Li Zhong; Giovanna E Hidalgo; Arnold J Stromberg; Nada H Khattar; James R Jett; Edward A Hirschowitz
Journal:  Am J Respir Crit Care Med       Date:  2005-08-18       Impact factor: 21.405

7.  Combining Shapley value and statistics to the analysis of gene expression data in children exposed to air pollution.

Authors:  Stefano Moretti; Danitsja van Leeuwen; Hans Gmuender; Stefano Bonassi; Joost van Delft; Jos Kleinjans; Fioravante Patrone; Domenico Franco Merlo
Journal:  BMC Bioinformatics       Date:  2008-09-02       Impact factor: 3.169

8.  Identification of multiple cancer/testis antigens by allogeneic antibody screening of a melanoma cell line library.

Authors:  Y T Chen; A O Güre; S Tsang; E Stockert; E Jäger; A Knuth; L J Old
Journal:  Proc Natl Acad Sci U S A       Date:  1998-06-09       Impact factor: 11.205

9.  Occurrence of autoantibodies to annexin I, 14-3-3 theta and LAMR1 in prediagnostic lung cancer sera.

Authors:  Ji Qiu; Gina Choi; Lin Li; Hong Wang; Sharon J Pitteri; Sandra R Pereira-Faca; Alexei L Krasnoselsky; Timothy W Randolph; Gilbert S Omenn; Cim Edelstein; Matt J Barnett; Mark D Thornquist; Gary E Goodman; Dean E Brenner; Ziding Feng; Samir M Hanash
Journal:  J Clin Oncol       Date:  2008-09-15       Impact factor: 44.544

10.  A novel fusion of RBM6 to CSF1R in acute megakaryoblastic leukemia.

Authors:  Ting-lei Gu; Thomas Mercher; Jeffrey W Tyner; Valerie L Goss; Denise K Walters; Melanie G Cornejo; Cynthia Reeves; Lana Popova; Kimberly Lee; Michael C Heinrich; John Rush; Masanori Daibata; Isao Miyoshi; D Gary Gilliland; Brian J Druker; Roberto D Polakiewicz
Journal:  Blood       Date:  2007-03-14       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.